NOT FOR DISTRIBUTION
Header cover image

Market Cap

US$5.4b

Last Updated

2021/04/13 22:13 UTC

Data Sources

Company Financials +

Executive Summary

Perrigo Company plc provides over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to prevent or treat conditions that can be self-managed. More Details


Snowflake Analysis

Average dividend payer and fair value.


Similar Companies

Share Price & News

How has Perrigo's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: PRGO is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 3% a week.

Volatility Over Time: PRGO's weekly volatility (3%) has been stable over the past year.


Market Performance


7 Day Return

-2.0%

PRGO

-0.2%

US Pharmaceuticals

1.3%

US Market


1 Year Return

-23.2%

PRGO

9.1%

US Pharmaceuticals

53.9%

US Market

Return vs Industry: PRGO underperformed the US Pharmaceuticals industry which returned 9.1% over the past year.

Return vs Market: PRGO underperformed the US Market which returned 53.9% over the past year.


Shareholder returns

PRGOIndustryMarket
7 Day-2.0%-0.2%1.3%
30 Day-2.1%-1.3%2.8%
90 Day-12.9%-1.8%6.6%
1 Year-21.7%-23.2%12.9%9.1%56.6%53.9%
3 Year-48.9%-51.3%29.7%19.6%62.7%52.3%
5 Year-67.3%-69.3%39.6%22.9%120.5%95.9%

Long-Term Price Volatility Vs. Market

How volatile is Perrigo's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Perrigo undervalued compared to its fair value and its price relative to the market?

37.0%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: PRGO ($40.15) is trading below our estimate of fair value ($63.74)

Significantly Below Fair Value: PRGO is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: PRGO is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.

PE vs Market: PRGO is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate PRGO's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: PRGO is good value based on its PB Ratio (0.9x) compared to the US Pharmaceuticals industry average (3.8x).


Future Growth

How is Perrigo forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

108.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: PRGO is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).

Earnings vs Market: PRGO is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: PRGO's is expected to become profitable in the next 3 years.

Revenue vs Market: PRGO's revenue is expected to decline over the next 3 years (-1.8% per year).

High Growth Revenue: PRGO's revenue is forecast to decline over the next 3 years (-1.8% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: PRGO's Return on Equity is forecast to be low in 3 years time (6.1%).


Past Performance

How has Perrigo performed over the past 5 years?

57.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: PRGO is currently unprofitable.

Growing Profit Margin: PRGO is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: PRGO is unprofitable, but has reduced losses over the past 5 years at a rate of 57.1% per year.

Accelerating Growth: Unable to compare PRGO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PRGO is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-1.8%).


Return on Equity

High ROE: PRGO has a negative Return on Equity (-2.88%), as it is currently unprofitable.


Financial Health

How is Perrigo's financial position?


Financial Position Analysis

Short Term Liabilities: PRGO's short term assets ($3.1B) exceed its short term liabilities ($1.4B).

Long Term Liabilities: PRGO's short term assets ($3.1B) do not cover its long term liabilities ($4.5B).


Debt to Equity History and Analysis

Debt Level: PRGO's debt to equity ratio (62.6%) is considered high.

Reducing Debt: PRGO's debt to equity ratio has increased from 59.8% to 62.6% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable PRGO has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: PRGO is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by 22.7% per year.


Dividend

What is Perrigo current dividend yield, its reliability and sustainability?

2.39%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: PRGO's dividend (2.39%) is higher than the bottom 25% of dividend payers in the US market (1.26%).

High Dividend: PRGO's dividend (2.39%) is low compared to the top 25% of dividend payers in the US market (3.5%).


Stability and Growth of Payments

Stable Dividend: PRGO's dividends per share have been stable in the past 10 years.

Growing Dividend: PRGO's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: PRGO is paying a dividend but the company is unprofitable.


Future Payout to Shareholders

Future Dividend Coverage: PRGO's dividends in 3 years are forecast to be well covered by earnings (39.1% payout ratio).


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.8yrs

Average management tenure


CEO

Murray Kessler (60 yo)

2.5yrs

Tenure

US$10,807,772

Compensation

Mr. Murray S. Kessler has been the Chief Executive Officer, President and Director of Perrigo Company plc since October 8, 2018. Mr. Kessler has more years of leadership experience in growing consumer prod...


CEO Compensation Analysis

Compensation vs Market: Murray's total compensation ($USD10.81M) is above average for companies of similar size in the US market ($USD6.39M).

Compensation vs Earnings: Murray's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: PRGO's management team is considered experienced (4.8 years average tenure).


Board Members

Experienced Board: PRGO's board of directors are considered experienced (3.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: PRGO insiders have sold more shares than they have bought in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Perrigo Company plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Perrigo Company plc
  • Ticker: PRGO
  • Exchange: NYSE
  • Founded: 1887
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$5.412b
  • Shares outstanding: 133.57m
  • Website: https://www.perrigo.com

Number of Employees


Location

  • Perrigo Company plc
  • The Sharp Building
  • Hogan Place
  • Dublin
  • Co. Dublin
  • 2
  • Ireland

Listings


Biography

Perrigo Company plc provides over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to prevent or treat conditions that can be self-managed. The com...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/04/13 22:13
End of Day Share Price2021/04/13 00:00
Earnings2020/12/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.